Zongertinib vs. Sevabertinib: Two Major Breakthroughs in HER2-Mutant Lung Cancer Treatment — What Are the Key Differences?

A side-by-side look at zongertinib (Hernexeos) and sevabertinib (Hyrnuo), the first two oral TKIs approved for HER2-mutant NSCLC, covering mechanism, clinical data, approvals, and safety.

Top Stories

From Intravenous Infusion to Oral Administration: Paclitaxel Oral Solution Gains a New Indication for Breast Cancer

KRAS Mutations and Precision Oncology: From KRAS G12C Inhibitors to Next-Generation RAS-Targeted Therapies

Latest Coverage

Global First-in-Class Drug Approved in China: Vosoritide Brings Disease-Modifying Treatment to Children with Achondroplasia
On September 18, 2026, the official website of China’s National Medical Products Administration (NMPA) announced that...

Complete Guide to Lung Cancer Treatment in China: Costs, Leading Hospitals, and What International Patients Should Know
Lung cancer is one of the most common cancers and a leading cause of cancer-related deaths worldwide. China records m...

Atopic Dermatitis Welcomes an Important New Treatment: China Approves Ruxolitinib Phosphate Cream for Children Aged 2 and Older and Adults
For patients living with atopic dermatitis (AD), the burden of the disease goes beyond redness, dry skin, and rashes....

What Is the Difference Between Acute and Chronic Leukemia? DengYue RX Explains Leukemia Types and Pharmaceutical Supply
Leukemia is a group of malignant blood disorders that affect the blood-forming tissues and is not a single disease. A...

Rituximab Procurement Options: Different Budget Solutions from Originator Drugs to Biosimilars
In the field of hematologic oncology, Rituximab is a classic targeted biologic with a long history of clinical use. S...

How to Submit a Medicine Request? A Guide to DengYue Pharmacy's Online Medicine Request Service
As the internet and digital services continue to become an increasingly important part of healthcare and the pharmace...

In-Depth Analysis

Zongertinib vs. Sevabertinib: Two Major Breakthroughs in HER2-Mutant Lung Cancer Treatment — What Are the Key Differences?

From Intravenous Infusion to Oral Administration: Paclitaxel Oral Solution Gains a New Indication for Breast Cancer

KRAS Mutations and Precision Oncology: From KRAS G12C Inhibitors to Next-Generation RAS-Targeted Therapies

Global First-in-Class Drug Approved in China: Vosoritide Brings Disease-Modifying Treatment to Children with Achondroplasia